{"id":54678,"date":"2023-03-09T13:06:35","date_gmt":"2023-03-09T12:06:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\/"},"modified":"2023-03-09T13:06:35","modified_gmt":"2023-03-09T12:06:35","slug":"seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\/","title":{"rendered":"Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference"},"content":{"rendered":"<div>\n<p>CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.serestherapeutics.com%2F&amp;esheet=53358121&amp;newsitemid=20230309005056&amp;lan=en-US&amp;anchor=Seres+Therapeutics%2C+Inc.&amp;index=1&amp;md5=1303d64bc8c24f0f0c4fb2a33b84bf1f\" rel=\"nofollow noopener\" shape=\"rect\">Seres Therapeutics, Inc.<\/a> (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023 at 8:40 a.m. ET.\n<\/p>\n<p>\nAn audio webcast of the presentation will be available under the \u201cInvestors and News\u201d section of Seres\u2019 website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.\n<\/p>\n<p>\n<b>About Seres Therapeutics<\/b>\n<\/p>\n<p>\nSeres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres\u2019 SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced to prevent further recurrences of <i>C. difficile<\/i> infection and has potential to become a first-in-class oral FDA-approved microbiome therapeutic. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.\n<\/p>\n<p>\nFor more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.serestherapeutics.com&amp;esheet=53358121&amp;newsitemid=20230309005056&amp;lan=en-US&amp;anchor=www.serestherapeutics.com&amp;index=2&amp;md5=eeb8c1e0f7d8226d015ba3e02aa93a2d\" rel=\"nofollow noopener\" shape=\"rect\">www.serestherapeutics.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>IR and PR Contact<\/b><br \/>Carlo Tanzi, Ph.D.<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;&#x74;&#111;:&#x63;&#116;&#x61;&#110;z&#x69;&#64;&#x73;&#101;r&#x65;s&#x74;&#104;&#x65;&#x72;a&#x70;&#101;&#x75;&#116;i&#x63;&#115;&#x2e;&#99;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x63;&#x74;&#97;&#110;&#122;i&#x40;&#x73;&#x65;&#114;&#101;st&#x68;&#x65;&#x72;&#97;&#112;e&#x75;&#x74;&#x69;&#99;&#115;&#46;c&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023 at 8:40 a.m. ET. An audio webcast of the presentation will be available &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54678","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023 at 8:40 a.m. ET. An audio webcast of the presentation will be available ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-09T12:06:35+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference\",\"datePublished\":\"2023-03-09T12:06:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\\\/\"},\"wordCount\":262,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\\\/\",\"name\":\"Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-03-09T12:06:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference - Pharma Trend","og_description":"CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023 at 8:40 a.m. ET. An audio webcast of the presentation will be available ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-09T12:06:35+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference","datePublished":"2023-03-09T12:06:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\/"},"wordCount":262,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\/","url":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\/","name":"Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-03-09T12:06:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/seres-therapeutics-to-participate-in-oppenheimer-33rd-annual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54678"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54678\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}